The beneficial effects of metformin on biochemical parameters and body weight in NAFLD patients were parallel to an increase in adiponectin levels [152,153] and a reduction in chemerin levels [151]. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.